Study details
Enrolling now
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer
Iovance Biotherapeutics, Inc.
NCT IDNCT06481592ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 5.1 years
Ages
18–70
Sex
Female only
Locations
12 sites in AZ, CA, FL +8
What this study is about
Researchers are testing a treatment called lifileucel for adults with advanced endometrial cancer. The trial will last about 1858 days and aims to see if this treatment is effective and safe.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Lifileucel
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
lifileucel
Endpoints
Primary: Objective Response Rate
Secondary: Adverse Events, Complete Response Rate, Disease Control Rate, Duration of Response, Overall Survival, Progression-Free Survival
Body systems
Oncology